The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

The FDA approves Spravato, a nasal spray derived from Ketamine, to help some people treat depression. Dr. Bill Hartman from UW Health shares more.

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.

Dr. Joao de Quevedo with UTHealth Houston shares what researchers found during a clinical trial for Spravato, the first FDA-approved nasal spray to treat depression.

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...

Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral antidepressants. On Tuesday, the Food and Drug Administration (FDA) ...

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...

A “frustrating” pause has delayed the roll-out of equipping and training Bristol police officers with an antidote for opioid ...

Vaccines, antibiotics, antiviral medications and anti-inflammatory drugs are all associated with a reduced risk of dementia, researchers reported in a study published Tuesday in the journal ...

Seniors have a 61% higher risk of stroke if their parents divorced when they were children or teenagers, researchers reported in a study published Wednesday in the journal PLOS One.